We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DENTSPLY (XRAY) Beats on Earnings in Q4, Misses Revenues
Read MoreHide Full Article
DENTSPLY SIRONA Inc. (XRAY - Free Report) reported adjusted earnings per share (EPS) of 67 cents in the fourth quarter of 2016, surpassing the Zacks Consensus Estimate by 2 cents. Earnings were also higher than 65 cents recorded in the year-ago quarter.
Stock Performance
The price performance of the stock has been unfavorable over the last three months. DENTSPLY SIRONA registered a paltry return of 0.47%, underperforming the Zacks classified Medical - Dental Supplies sub-industry’s gain of almost 6.64%.
Quarter Details
Net sales increased to $996.5 million from $671.1 million in the year-ago period. However, the figure came below the Zacks Consensus Estimate of $1,019.0 million. Sales of the combined businesses increased 4.3% at constant currency (cc) exchange rates. In the reported quarter sales were affected by channel inventory reduction related to a change in distribution strategy in North America.
In the quarter, U.S. sales surged 48.2% to $329.0 million, while net sales in Europe increased 37.7% to $402.4 million. Sales of the combined business declined 5.1% at cc in the U.S., while European sales rose 7.9%.
Net sales in Rest of World increased 69.0% to $265.1 million. Sales in Rest of World of the combined businesses improved 12.5% at cc.
Segment Details
The business is organized into two reporting segments: Dental & Healthcare Consumables and Technologies.
Dental & Healthcare Consumables comprises preventive, restorative, instruments, endodontic and laboratory dental products, as well as consumable medical device products. Sales increased 5.6% to $513.3 million. At cc, sales of the combined entity rose 3.4% year over year in the quarter.
Technologies consist of dental implants, CAD/CAM systems, imaging systems, treatment centers and orthodontic products. Net sales increased 160.9% to $483.2 million. At cc, sales of the combined business climbed 5.2% in the quarter.
Financial Update
Total cash and cash equivalents of the company increased to $383.9 million as of Dec 31, 2016 from $284.6 million as of Dec 31, 2015.
Cash generated from operations in 2016 was $563.4 million compared with $497.4 million in 2015.
As of Dec 31, 2016, DaVita’s long-term debt was $1.5 billion, up from $1.1 billion at year-end 2015.
Guidance
For full-year 2017, the company anticipates adjusted EPS in the range of $2.80 to $2.90.
DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise
Currently, DENTSPLY carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the broader medical sector include Glaukos Corporation (GKOS - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corporation . Notably, Glaukos sports a Zacks Rank #1 (Strong Buy) while Avinger and Fluidigm carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock registered an impressive one-year return of 180.8%.
Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% last quarter.
Fluidigm Corporation has a long-term expected earnings growth of 25%. The stock has added 10.3% over the last one-year.
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DENTSPLY (XRAY) Beats on Earnings in Q4, Misses Revenues
DENTSPLY SIRONA Inc. (XRAY - Free Report) reported adjusted earnings per share (EPS) of 67 cents in the fourth quarter of 2016, surpassing the Zacks Consensus Estimate by 2 cents. Earnings were also higher than 65 cents recorded in the year-ago quarter.
Stock Performance
The price performance of the stock has been unfavorable over the last three months. DENTSPLY SIRONA registered a paltry return of 0.47%, underperforming the Zacks classified Medical - Dental Supplies sub-industry’s gain of almost 6.64%.
Quarter Details
Net sales increased to $996.5 million from $671.1 million in the year-ago period. However, the figure came below the Zacks Consensus Estimate of $1,019.0 million. Sales of the combined businesses increased 4.3% at constant currency (cc) exchange rates. In the reported quarter sales were affected by channel inventory reduction related to a change in distribution strategy in North America.
In the quarter, U.S. sales surged 48.2% to $329.0 million, while net sales in Europe increased 37.7% to $402.4 million. Sales of the combined business declined 5.1% at cc in the U.S., while European sales rose 7.9%.
Net sales in Rest of World increased 69.0% to $265.1 million. Sales in Rest of World of the combined businesses improved 12.5% at cc.
Segment Details
The business is organized into two reporting segments: Dental & Healthcare Consumables and Technologies.
Dental & Healthcare Consumables comprises preventive, restorative, instruments, endodontic and laboratory dental products, as well as consumable medical device products. Sales increased 5.6% to $513.3 million. At cc, sales of the combined entity rose 3.4% year over year in the quarter.
Technologies consist of dental implants, CAD/CAM systems, imaging systems, treatment centers and orthodontic products. Net sales increased 160.9% to $483.2 million. At cc, sales of the combined business climbed 5.2% in the quarter.
Financial Update
Total cash and cash equivalents of the company increased to $383.9 million as of Dec 31, 2016 from $284.6 million as of Dec 31, 2015.
Cash generated from operations in 2016 was $563.4 million compared with $497.4 million in 2015.
As of Dec 31, 2016, DaVita’s long-term debt was $1.5 billion, up from $1.1 billion at year-end 2015.
Guidance
For full-year 2017, the company anticipates adjusted EPS in the range of $2.80 to $2.90.
DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise
DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise | DENTSPLY SIRONA Inc. Quote
Zacks Rank & Key Picks
Currently, DENTSPLY carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the broader medical sector include Glaukos Corporation (GKOS - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corporation . Notably, Glaukos sports a Zacks Rank #1 (Strong Buy) while Avinger and Fluidigm carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock registered an impressive one-year return of 180.8%.
Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% last quarter.
Fluidigm Corporation has a long-term expected earnings growth of 25%. The stock has added 10.3% over the last one-year.
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>